Revisiting 5α-reductase inhibitors and the risk of prostate cancer

Cindy H. Chau; William D. Figg

doi:10.1038/s41585-018-0018-9

Revisiting 5α-reductase inhibitors and the risk of prostate cancer

Cindy H. Chau, William D. Figg^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

The role of 5α-reductase inhibitors (5-ARI) in prostate cancer chemoprevention remains a controversy, as cancer prevention trials with 5-ARIs have shown a decreased incidence of low-grade prostate cancer but a potential increased risk in high-grade disease. Recent studies have shed light on the long-term safety of 5-ARIs in terms of influencing prostate cancer risk.

Original language	English
Pages (from-to)	400-401
Number of pages	2
Journal	Nature Reviews Urology
Volume	15
Issue number	7
DOIs	https://doi.org/10.1038/s41585-018-0018-9
State	Published - 1 Jul 2018
Externally published	Yes

Access to Document

10.1038/s41585-018-0018-9

Cite this

@article{132a036d473645eea924e867e868c6cc,

title = "Revisiting 5α-reductase inhibitors and the risk of prostate cancer",

abstract = "The role of 5α-reductase inhibitors (5-ARI) in prostate cancer chemoprevention remains a controversy, as cancer prevention trials with 5-ARIs have shown a decreased incidence of low-grade prostate cancer but a potential increased risk in high-grade disease. Recent studies have shed light on the long-term safety of 5-ARIs in terms of influencing prostate cancer risk.",

author = "Chau, {Cindy H.} and Figg, {William D.}",

note = "Publisher Copyright: {\textcopyright} 2018 Macmillan Publishers Ltd., part of Springer Nature.",

year = "2018",

month = jul,

day = "1",

doi = "10.1038/s41585-018-0018-9",

language = "English",

volume = "15",

pages = "400--401",

journal = "Nature Reviews Urology",

issn = "1759-4812",

number = "7",

}

TY - JOUR

T1 - Revisiting 5α-reductase inhibitors and the risk of prostate cancer

AU - Chau, Cindy H.

AU - Figg, William D.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The role of 5α-reductase inhibitors (5-ARI) in prostate cancer chemoprevention remains a controversy, as cancer prevention trials with 5-ARIs have shown a decreased incidence of low-grade prostate cancer but a potential increased risk in high-grade disease. Recent studies have shed light on the long-term safety of 5-ARIs in terms of influencing prostate cancer risk.

AB - The role of 5α-reductase inhibitors (5-ARI) in prostate cancer chemoprevention remains a controversy, as cancer prevention trials with 5-ARIs have shown a decreased incidence of low-grade prostate cancer but a potential increased risk in high-grade disease. Recent studies have shed light on the long-term safety of 5-ARIs in terms of influencing prostate cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=85046788592&partnerID=8YFLogxK

U2 - 10.1038/s41585-018-0018-9

DO - 10.1038/s41585-018-0018-9

M3 - Review article

C2 - 29740116

AN - SCOPUS:85046788592

SN - 1759-4812

VL - 15

SP - 400

EP - 401

JO - Nature Reviews Urology

JF - Nature Reviews Urology

IS - 7

ER -

Revisiting 5α-reductase inhibitors and the risk of prostate cancer

Abstract

Access to Document

Fingerprint

Cite this